Cancer Survivor Clinical Trial
Official title:
A Phase II Study of the Determinants of Transdermal Drug Delivery to the Normal and the Radiated Breast
This phase II trial studies how well topical afimoxifene works in treating patients with breast cancer who have undergone radiation therapy on one breast. Topical afimoxifene is a quick-drying medicated gel that may block the growth of breast cancer cells when applied to the breast skin. The purpose of this research is to determine what effect, if any, differences in skin type between women have on the delivery of topical afimoxifene to the breast tissue, and whether radiation affects the delivery of topical afimoxifene to breast tissue.
Status | Recruiting |
Enrollment | 156 |
Est. completion date | June 25, 2024 |
Est. primary completion date | January 31, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients must have received prior unilateral breast radiotherapy (RT) for ductal breast carcinoma in situ (DCIS) or invasive cancer (>= 12 weeks after the end of RT), and have an intact unradiated (non-RT) breast. - Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%). - A prior history of malignancy is allowed, as long as the patient is considered to have ?no evaluable disease? and cancer treatment has been completed. - Females of child-bearing potential (FOCBP) and male partners of female participants must agree to use TWO effective forms of birth control (abstinence is not an allowed method) prior to study entry and for the duration of study participation, and for two months following the last dose of study medications. Effective birth control methods are: copper IUD (intrauterine device), diaphragm/cervical cap/shield, spermicide, contraceptive sponge, condoms. Should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. - NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: - Has not undergone a hysterectomy or bilateral oophorectomy - Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months). - FOCBP must have a negative urine pregnancy test within 7 days prior to registration on study. - Willingness to avoid exposing breast skin to natural or artificial sunlight (i.e. tanning beds) for the duration of the study drug use. - Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study. Exclusion Criteria: - Patients receiving any other investigational agents within 30 days of registration are not eligible. - Patients currently using oral selective estrogen receptor modulators (SERMS) (tamoxifen, raloxifene, bazedoxifene) are not eligible. - Note: Prior or current endocrine therapy other than SERMs are allowed. - Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition afimoxifene (4-OHT) are not eligible. - Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following, are not eligible: - Hypertension that is not controlled on medication - Ongoing or active infection requiring systemic treatment - Symptomatic congestive heart failure - Unstable angina pectoris - Cardiac arrhythmia - Psychiatric illness/social situations that would limit compliance with study requirements - Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient?s safety or study endpoints. - Female patients who are pregnant or nursing are not eligible. - Patients with prior bilateral breast cancer radiotherapy or radiotherapy for lymphoma will be excluded. - Patients with skin lesions on the breast that disrupt the stratum corneum (e.g. eczema, ulceration) are not eligible. - Patients with a history of endometrial neoplasia are not eligible. - Patients with a history of thromboembolic disease are not eligible. - Note: history of varicose veins and superficial phlebitis is allowed. - Patients who are undergoing active treatment for any malignancy will be excluded. - Male patients are excluded from this study since there are no data regarding skin penetration of 4-OHT though male chest wall skin (which is thicker and hairier than female chest wall skin). |
Country | Name | City | State |
---|---|---|---|
United States | Northwestern University | Chicago | Illinois |
United States | University of Illinois Cancer Center | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Northwestern University | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determinants of inter-individual variation in afimoxifene drug concentrations in unradiated breast tissue related to skin histology, blood and lymph vessel density | Univariate analyses will relate each characteristic to tissue drug concentration using either correlation analysis for continuous characteristics or a t-test, analysis of variance or rank sum test for categorical characteristics. Multiple linear regression modelling will be used to select those characteristics that provide the strongest independent contribution to the model. | Up to 35 days post-treatment | |
Primary | Determinants of inter-individual variation in afimoxifene drug concentrations in unradiated breast tissue related to the expression of xenobiotic transporters and enzymes | Univariate analyses will relate each characteristic to tissue drug concentration using either correlation analysis for continuous characteristics or a t-test, analysis of variance or rank sum test for categorical characteristics. Multiple linear regression modelling will be used to select those characteristics that provide the strongest independent contribution to the model. | Up to 35 days post-treatment | |
Primary | Determinants of inter-individual variation in afimoxifene drug concentrations in unradiated breast tissue related to skin features | Will be measured with confocal reflectance microscopy. Univariate analyses will relate each characteristic to tissue drug concentration using either correlation analysis for continuous characteristics or a t-test, analysis of variance or rank sum test for categorical characteristics. Multiple linear regression modelling will be used to select those characteristics that provide the strongest independent contribution to the model. A similar analysis will be conducted using the skin characteristics from the confocal reflectance microscopy. | Up to 35 days pot-treatment | |
Secondary | Effect of breast radiotherapy on drug concentrations resulting from transdermal delivery of afimoxifene (4-OHT) | Tissue drug concentrations will be compared between radiated and non-radiated breasts using a mixed linear model, with breast radiation status as a fixed effect of interest and person as a random effect. Analyses will also be done to compare the skin data (histology, immunohistochemistry [IHC], protein expression, CRS) between radiated and non-radiated breasts. While most characteristics will be continuous, other metrics will be analyzed by using different link functions in similarly constructed generalized linear model. | Up to 35 days post-treatment | |
Secondary | Differences between radiated and non-radiated skin and breast tissue that contribute to differences in permeation | Tissue drug concentrations will be compared between radiated and non-radiated breasts using a mixed linear model, with breast radiation status as a fixed effect of interest and person as a random effect. Analyses will also be done to compare the skin data (histology, IHC, protein expression, CRS) between radiated and non-radiated breasts. While most characteristics will be continuous, other metrics will be analyzed by using different link functions in similarly constructed generalized linear model. | Up to 35 days post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02235051 -
Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors
|
N/A | |
Completed |
NCT01439945 -
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02194387 -
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
|
N/A | |
Completed |
NCT01641068 -
Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms
|
N/A | |
Not yet recruiting |
NCT05403671 -
Fit for Everyday Life - Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer
|
N/A | |
Completed |
NCT00246818 -
Effect of Tai Chi Vs. Structured Exercise on Physical Fitness and Stress in Cancer Survivors
|
Phase 2 | |
Completed |
NCT02559557 -
Culturally Adapted Parenting Intervention for Spanish-Speaking Parents in Improving Outcomes of Younger Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Survivors at Risk for Late Neurocognitive Effects
|
N/A | |
Completed |
NCT00956475 -
Quality of Life in Younger Leukemia and Lymphoma Survivors
|
Phase 1 | |
Completed |
NCT02032121 -
Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors
|
N/A | |
Completed |
NCT00932997 -
Survivorship Booklets With or Without Individual Telephone Sessions in Increasing Knowledge About the Impact of Breast Cancer in African American and Latina Breast Cancer Survivors
|
N/A | |
Completed |
NCT02566408 -
Attitudes, Beliefs, and Preferences of Older Stage I-III Breast Cancer Survivors Towards Physical Activity
|
N/A | |
Completed |
NCT02985411 -
Harvest for Health in Older Cancer Survivors
|
N/A | |
Completed |
NCT00915889 -
Psychosocial Support for African-American, Latina-American, or European-American Cervical Cancer Survivors
|
N/A | |
Completed |
NCT02518308 -
Mindfulness Intervention in Reducing Anxiety in Patients Who Have Been Treated for Gynecologic Cancer
|
N/A | |
Completed |
NCT03307044 -
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
|
N/A | |
Terminated |
NCT03781778 -
Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors
|
Phase 2 | |
Completed |
NCT03520283 -
Systems Support Mapping in Guiding Self-Management in Stage I-III Colorectal Cancer Survivors
|
N/A | |
Completed |
NCT02662335 -
Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT01347970 -
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial
|
Phase 2 | |
Completed |
NCT00713505 -
Educational and Skills Training Program for Parents of Childhood Cancer Survivors Who Have Neurobehavioral Dysfunction
|
N/A |